Page 14 - PCIRN-annual-report-2014-flipbook

PUBLICATIONS, ABSTRACTS AND PRESENTATIONS CLINICAL TRIALS Rubinstein E, Predy G, Sauvé L, Hammond G, Aoki F, Sikora C, Law B, Halperin S, Scheifele D. First Nations and Métis adults Responded Well to Adjuvanted H1N12009 Pandemic Vaccine. CMAJ 2011, 183(13):e1033-7. Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA. Evaluation of Adjuvanted Pandemic H1N12009 Infuenza Vaccine After One and Two Doses in Young Children. Pediatric Infect Dis J. 2011;30:402-7 Scheifele DW, Marty K, Lajeunesse C, Fan SY, Bjornson G, Langley JM, Halperin SA. Strategies for Successful Rapid Trials of Infuenza Vaccine. Clinical Trials. December 2011; 8:699-704. Langley JM, Scheifele DW, Quach C, Vanderkooi O, Dobson S, Ward B, Kellner J, McNeil S, MacKinnon-Cameron D, Smith B, Halperin SA. Safety and immunogenicity of 2010-2011 H1N1/2009-containing trivalent inactivated infuenza vaccine in children 12 to 59 months of age who received ASO3-adjuvanted H1N1/2009 pandemic vaccine. Vaccine 2012: 30:3389-3394. Scheifele DW, Dionne M, Ward BJ, Cooper C, Vanderkooi OG, Li Y, Halperin SA. Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated infuenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial. Human Vaccines & Immunotherapeutics 2013; 9(1):1-8. (RT06, in 2010) Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, Li Y. Compatibility of AS03-adjuvanted A/H1N1pdm2009 and seasonal trivalent inactivated infuenza vaccines in adults: results of a randomized, controlled trial. Vaccine 2012;30:4728-4732. Al-Dabbagh M, Lapphra K, Scheifele DW, Halperin SA, Langley JM, Cho P, Kollmann TR, Li Y, De Serres G, Fortuno ES 3rd, Bettinger JA. Elevated infammatory mediators in adults with oculorespiratory syndrome following infuenza immunization: a public health agency of Canada/Canadian Institutes of Health Research Infuenza Research Network Study. Clin Vaccine Immunol. 2013 Aug;20(8):1108-14. doi: 10.1128/CVI.00659-12. Epub 2013 May 22. Lapphra K, Huh L, Scheifele DW. Adverse Neurologic reactions after both doses of pandemic H1N1 infuenza vaccine with optic neuritis and demyelination. PIJD 2011; 30 (1): 84-6. Safety, Immunogenicity and Tolerability of Three Infuenza Vaccines for Older Adults: Results of a Randomized, Controlled Comparison. Scheifele DW, McNeial S, Ward B, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Li Y, Montomoli E, Schneeberg A, Bettinger J, Hatchette, T Halperin SA, PHAC/CIHR Infuenza Research Network Under review Scheifele DW, Ward B, Dionne M, De Serres G, Langley J, Halperin S, Vanderkooi O, Kellner J, Dobson S, Sauvé L, Li Y, Law B. One Dose or Two? Results of a PCIRN Study of Dosing Requirements of Toddlers Given Adjuvanted H1N1 Infuenza Vaccine During the 2009 Pandemic [abstract]. Can J Infect Dis Med Microbiol. 2010;21:181. Abstract O016. Scheifele DW, Ward B, Dionne M, De Serres G, Langley J, Halperin S, Vanderkooi O, Kellner J, Dobson S, Sauvé LJ, Kollmann T. Immunogenicity of AS03-Adjuvanted pH1N1 Infuenza Vaccine in Young Canadian Children [abstract]. In: Abstracts of the 48th Annual Meeting of Infectious Diseases Society of America; 2010 Oct 21–24; Vancouver, BC. Abstract Poster 1354. Scheifele DW, Ward B, Dionne M, De Serres G, Halperin S, Vanderkooi O, Kellner J, Dobson S, Sauvé LJ, Kollmann T. Safety of an AS03-Adjuvanted pH1N1 Infuenza Vaccine Given to Young Canadian Children [abstract]. In: Abstracts of the 48th Annual Meeting of Infectious Diseases Society of America; 2010 Oct 21–24; Vancouver, BC. Abstract Poster 1363. Scheifele DW, Dionne M, De Serres G, Loeb M, McGeer A, Vanderkooi O, Kellner J, Dobson S, Sauvé L, Li Y, Law B, Halperin S. PCIRN Study of Adults Given Monovalent, Adjuvanted H1N1 Vaccine with Concurrent or Delayed Trivalent Seasonal Infuenza Vaccination [abstract]. In: Abstracts of the 9th Canadian Immunization Conference; 2010 December 5-8; Quebec City, QC. Abstract Poster P141. Also, Can J Infect Dis Med Microbiol 2010; 21(4):173-234 Cooper C, Haase D, Walmsley S, Klein M, Scheifele DW, Halperin S, Li Y, Law B, Smith B. PCIRN Randomized Trial to Compare the Immunogenicity of Adjuvanted Pandemic H1N1 2009 Vaccine with or Without a Second “Booster” Dose in HIV-infected Adults [abstract]. In: Abstracts of the 9th Canadian Immunization Conference; 2010 December 5-8; Quebec City, QC. Abstract Poster P116. Also, Can J Infect Dis Med Microbiol 2010; 21(4):173-234 Scheifele DW, Dionne M, De Serres G, Loeb M, McGeer A, Vanderkooi O, Kellner J, Dobson, S, Sauvé LJ, Li Y, Law B, Halperin SA. PCIRN Study of Adults Given Monovalent, Adjuvanted H1N1 Vaccine With Concurrent or Delayed Trivalent Seasonal Infuenza Vaccination [abstract]. In: Abstracts of the 9th Canadian Immunization Conference; 2010 December 5-8; Quebec City, QC. Abstract Poster 141. Also, Can J Infect Dis Med Microbiol 2010; 21(4):173-234 Schiefele, DW. PCIRN Rapid Trials Theme, Year 1 and Year 2 Research Activities. Presented at: CIHR Pandemic Preparedness Conference (PPRSI); 2010 November 12-13; Ottawa, ON. Scheifele, DW. PCIRN Rapid Trials Theme, Year 1 and Year 2 Research Activities. Presented at: 9th Canadian Immunization Conference; 2010 December 5-8; Quebec City, QC. Cooper, C. Immediate and Long-term Immunogenicity and Effcacy of Adjuvanted Pandemic H1N12009 Vaccine With or Without Booster: A Randomized Trial in HIV Infected Adults. Presented at: 20th Annual Canadian Conference on HIV/AIDS Research; 2011 Apr 14-17; Toronto, ON. Oral Abstract 089. Also, Can J Infect Dis Med Microbiol 2011; 22(Suppl.B):35B-36B. Scheifele, DW. Safety and Immunogencity of Re-vaccination with H1N1-containing 2010-11 Seasonal Infuenza Vaccine After Priming with 2009 Adjuvanted Pandemic Vaccine. Presented at: 14th Annual Conference on Vaccine Research of the National Foundation for Infectious Diseases; 2011 May 16-18; Bethesda, Maryland. Langley, JM. Rapid Pre-season Trial of the Safety of 2010-2011 H1N12009-containing Trivalent Inactivated Infuenza Vaccine (TIV) in Young Children 12 to 59 months of Age (YC) Who Received AS03-adjuvanted H1N12009 Pandemic Vaccine. Presented at: 14th Annual Conference on Vaccine Research of the National Foundation for Infectious Diseases; 2011 May 16-18; Bethesda, Maryland. An Investigation of Infammatory Mediators in Selected Adverse Events following Infuenza Immunization in Adults. Al-Dabbagh M, Lapphra K, Scheifele D, Dobson S, th Halperin S, Langley J, De Serres G, Kollmann T, Bettinger J. Poster presented at the 5 Annual Global Vaccine ISV Congress, October 2-4, 2011, Seattle, WA USA Knowledge, Attitudes and Beliefs of Older Adults about Pneumococcal Immunization. Schneeberg, Amy; Bettinger, Julie A.; McNeil, Shelly; Ward, Brian; Dionne, Marc; Cooper, Curtis; Coleman, Brenda; Loeb, Mark; Rubinstein, Ethan; McElhaney, Janet; Scheifele, David; Halperin, Scott. Oral Abstract presented at the 2012 Canadian Immunization Conference, Vancouver, BC, December 2012 Randomized Controlled Comparisoin of 3 Seasonal Infuenza Vaccines in Canadian Seniors: Immunogenicity Data from a PCIRN Trial. Scheifele, David McNeil, Shelley Dionne, Marc Ward, Brian; Cooper, Curtis Loeb, Mark; Coleman, Brenda McGeer, Allison Rubinstein, Ethan McElhaney, Janet Li, Yan Hatchette, Todd; Halperin , Scott. Oral Abstract presented at the 2012 Canadian Immunization Conference, Vancouver, BC, December 2012 Randomized Controlled Comparison of 3 Seasonal Infuenza Vaccines in Canadian Seniors: Safety Observations from a PCIRN Trial. Scheifele, David McNeil, Shelley Dionne, Marc Ward, Brian; Cooper, Curtis Loeb, Mark; Coleman, Brenda McGeer, Allison Rubinstein, Ethan McElhaney, Janet Li, Yan Halperin , Scott . Poster Abstract presented at the 2012 Canadian Immunization Conference, Vancouver, BC, December 2012 PHAC/CIHR INFLUENZA RESEARCH NETWORK